These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16725321)

  • 1. Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.
    Sperandio D; Tai VW; Lohman J; Hirschbein B; Mendonca R; Lee CS; Spencer JR; Janc J; Nguyen M; Beltman J; Sprengeler P; Scheerens H; Lin T; Liu L; Gadre A; Kellogg A; Green MJ; McGrath ME
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4085-9. PubMed ID: 16725321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological activity of potent and selective inhibitors of mast cell tryptase.
    Hopkins CR; Czekaj M; Kaye SS; Gao Z; Pribish J; Pauls H; Liang G; Sides K; Cramer D; Cairns J; Luo Y; Lim HK; Vaz R; Rebello S; Maignan S; Dupuy A; Mathieu M; Levell J
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2734-7. PubMed ID: 15911249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.
    Palmer JT; Rydzewski RM; Mendonca RV; Sperandio D; Spencer JR; Hirschbein BL; Lohman J; Beltman J; Nguyen M; Liu L
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3434-9. PubMed ID: 16644215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase.
    Vaz RJ; Gao Z; Pribish J; Chen X; Levell J; Davis L; Albert E; Brollo M; Ugolini A; Cramer DM; Cairns J; Sides K; Liu F; Kwong J; Kang J; Rebello S; Elliot M; Lim H; Chellaraj V; Singleton RW; Li Y
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6053-6. PubMed ID: 15546728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of novel, potent, and selective human beta-tryptase inhibitors based on alpha-keto-[1,2,4]-oxadiazoles.
    Lee CS; Liu W; Sprengeler PA; Somoza JR; Janc JW; Sperandio D; Spencer JR; Green MJ; McGrath ME
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4036-40. PubMed ID: 16714109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel pyrazinone inhibitors of mast cell tryptase: synthesis and SAR evaluation.
    Hopkins C; Neuenschwander K; Scotese A; Jackson S; Nieduzak T; Pauls H; Liang G; Sides K; Cramer D; Cairns J; Maignan S; Mathieu M
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4819-23. PubMed ID: 15341931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.
    Sutton JC; Bolton SA; Davis ME; Hartl KS; Jacobson B; Mathur A; Ogletree ML; Slusarchyk WA; Zahler R; Seiler SM; Bisacchi GS
    Bioorg Med Chem Lett; 2004 May; 14(9):2233-9. PubMed ID: 15081015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase.
    Bisacchi GS; Slusarchyk WA; Bolton SA; Hartl KS; Jacobs G; Mathur A; Meng W; Ogletree ML; Pi Z; Sutton JC; Treuner U; Zahler R; Zhao G; Seiler SM
    Bioorg Med Chem Lett; 2004 May; 14(9):2227-31. PubMed ID: 15081014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.
    Duffy JL; Kirk BA; Wang L; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 May; 17(10):2879-85. PubMed ID: 17350841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of betaII tryptase.
    Levell J; Astles P; Eastwood P; Cairns J; Houille O; Aldous S; Merriman G; Whiteley B; Pribish J; Czekaj M; Liang G; Maignan S; Guilloteau JP; Dupuy A; Davidson J; Harrison T; Morley A; Watson S; Fenton G; McCarthy C; Romano J; Mathew R; Engers D; Gardyan M; Sides K; Kwong J; Tsay J; Rebello S; Shen L; Wang J; Luo Y; Giardino O; Lim HK; Smith K; Pauls H
    Bioorg Med Chem; 2005 Apr; 13(8):2859-72. PubMed ID: 15781396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease.
    Clarke MO; Byun D; Chen X; Doerffler E; Leavitt SA; Sheng XC; Yang CY; Kim CU
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1095-8. PubMed ID: 22189140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based library design and the discovery of a potent and selective mast cell β-tryptase inhibitor as an oral therapeutic agent.
    Liang G; Aldous S; Merriman G; Levell J; Pribish J; Cairns J; Chen X; Maignan S; Mathieu M; Tsay J; Sides K; Rebello S; Whitely B; Morize I; Pauls HW
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1049-54. PubMed ID: 22192588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.
    Xu J; Wei L; Mathvink RJ; Edmondson SD; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5373-7. PubMed ID: 16919457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of tryptase inhibitors derived from thalidomide.
    Tetsuhashi M; Ishikawa M; Hashimoto M; Hashimoto Y; Aoyama H
    Bioorg Med Chem; 2010 Jul; 18(14):5323-38. PubMed ID: 20561792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Hu Y; Xiang JS; DiGrandi MJ; Du X; Ipek M; Laakso LM; Li J; Li W; Rush TS; Schmid J; Skotnicki JS; Tam S; Thomason JR; Wang Q; Levin JI
    Bioorg Med Chem; 2005 Dec; 13(24):6629-44. PubMed ID: 16216515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dibasic inhibitors of human mast cell tryptase. Part 3: identification of a series of potent and selective inhibitors containing the benzamidine functionality.
    Dener JM; Rice KD; Newcomb WS; Wang VR; Young WB; Gangloff AR; Kuo EY; Cregar L; Putnam D; Wong M
    Bioorg Med Chem Lett; 2001 Jul; 11(13):1629-33. PubMed ID: 11425524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors.
    Patel D; Jain M; Shah SR; Bahekar R; Jadav P; Joharapurkar A; Dhanesha N; Shaikh M; Sairam KV; Kapadnis P
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1111-7. PubMed ID: 22189136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of 4-substituted benzylamine derivatives as beta-tryptase inhibitors.
    Miyazaki Y; Kato Y; Manabe T; Shimada H; Mizuno M; Egusa T; Ohkouchi M; Shiromizu I; Matsusue T; Yamamoto I
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2986-90. PubMed ID: 16540315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa).
    Polla MO; Tottie L; Nordén C; Linschoten M; Müsil D; Trumpp-Kallmeyer S; Aukrust IR; Ringom R; Holm KH; Neset SM; Sandberg M; Thurmond J; Yu P; Hategan G; Anderson H
    Bioorg Med Chem; 2004 Mar; 12(5):1151-75. PubMed ID: 14980627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives.
    Costanzo MJ; Yabut SC; Zhang HC; White KB; de Garavilla L; Wang Y; Minor LK; Tounge BA; Barnakov AN; Lewandowski F; Milligan C; Spurlino JC; Abraham WM; Boswell-Smith V; Page CP; Maryanoff BE
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2114-21. PubMed ID: 18272363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.